EU approves CSL Behring's Privigen for CIDP

04/8/2013 | Pharmaceutical Business Review Online

The European Commission granted CSL Behring approval to market Privigen, an intravenous immune globulin, as a treatment for chronic inflammatory demyelinating polyneuropathy. Positive results from the Privigen Impact on Mobility and Autonomy trial were cited in the application.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA